Category: 3. Business

  • John Van Der Wielen appointed Gold Corporation chair

    John Van Der Wielen appointed Gold Corporation chair

    • Former Crown Perth chair and HBF chief executive
      to chair The Perth Mint
    • John Van Der Wielen succeeds Sam Walsh in role
    • Appointment heralds new era for Gold Corporation
      under strengthened legislation

    Mines and Petroleum
    Minister David Michael today announced the appointment of John Van Der Wielen
    as the new non-executive chair of Gold Corporation, the operator of The Perth
    Mint.

    Mr Van Der Wielen will
    assume the role on 1 January 2026 for an initial two-year term.

    He succeeds Sam Walsh,
    who has left Gold Corporation after nearly seven years of service.

    Mr Van Der Wielen joins
    Gold Corporation following a distinguished career of more than 30 years across
    business, health insurance, banking and wealth management which included the
    international markets of London, Hong Kong, Singapore and Luxembourg.

    Notably he previously served
    as HBF chief executive for more than five years and Crown Perth chair for more
    than three years.

    He is also the current
    chair of ASX-listed regenerative medicine company Orthocell and chairs the WA
    Government’s Future Health Research and Innovation Fund.

    Mr Van Der Wielen’s appointment is timely as Gold
    Corporation enters a new era under new legislation aimed at standardising and
    strengthening governance and oversight.

    The Gold Corporation Amendment Bill 2025
    will bring Gold Corporation in line with other Government Trading Enterprises
    by updating and standardising its strategic planning, financial management and
    corporate governance practices.

    Comments attributed to Mines and Petroleum Minister David Michael:

    “I congratulate Mr Van
    Der Wielen on his appointment and look forward to working with him as Gold
    Corporation enters a new era under strengthened legislation aimed at improving
    governance and oversight.

    “Mr Van Der Wielen brings
    a wealth of expertise and experience to the role, including important knowledge
    and capabilities in corporate governance and anti-money laundering.

    “He chaired Crown Perth post
    the Royal Commission into the groupand managed the full remediation and
    successful re-issue of its casino licence working with the independent monitor
    appointed by the WA Government.

    “I would also like to thank Sam Walsh for his
    dedicated and professional service on the board of the Gold Corporation over
    nearly seven years.

    “Sam led the organisation through some
    challenging times and was instrumental in overseeing The Perth Mint’s
    Anti-Money Laundering Remediation Program, which addressed systems and
    processes to fix historical non-compliance issues.”

    Continue Reading

  • Interim share buyback programme | Rolls-Royce

    Interim share buyback programme | Rolls-Royce

    Rolls-Royce Holdings plc (Rolls-Royce or the Company) (LSE: RR., ADR: RYCEY) announces that, following the completion in November 2025 of its £1 billion share buyback programme for 2025, it will commence an interim irrevocable, non-discretionary programme to repurchase ordinary shares up to the value of £200 million (the Programme). The Programme will be undertaken ahead of the expected communication of the Company’s 2025 full year results on 26 February 2026 (the FY25 Results). The total quantum of share buybacks for 2026 remains subject to Board review and approval and is expected to be announced alongside the FY25 Results.

    The Programme will run from 2 January 2026 and is expected to complete no later than 24 February 2026. The Company has entered into a non-discretionary agreement (the Agreement) with UBS AG London Branch (UBS) to undertake the Programme on its behalf by making market purchases, as riskless principal, of the Company’s ordinary shares of 20 pence each (the Shares) on the London Stock Exchange or another recognised investment exchange. UBS will make trading decisions under the Programme independently of the Company, subject to certain parameters agreed between UBS and the Company prior to the commencement of the Programme and to the Company’s right to terminate the Agreement in certain limited circumstances.

    Shares acquired by UBS under the Agreement will be sold on to the Company and will be cancelled. The purpose of the Programme is therefore to reduce the Company’s share capital. The maximum number of Shares that may be acquired under the Programme, as authorised by shareholders at the Company’s 2025 Annual General Meeting on 1 May 2025, is 850,489,698.

    Any purchase of Shares under the Programme will be executed in accordance with the Company’s general authority to repurchase Shares granted at its 2025 Annual General Meeting, the Market Abuse Regulation 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 (both as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Chapter 9 of the Financial Conduct Authority’s UK Listing Rules.

    Repurchases of Shares under the Programme will be announced no later than 7.30 a.m. on the business day following the calendar day on which the repurchase occurred (or otherwise as required under the UK Listing Rules).

     

    For further information, please contact:

    Investors:
    Jeremy Bragg
    Head of Investor Relations, Rolls-Royce plc
    Tel +44 (0) 7795 840875
    [email protected]

    Media:
    Richard Wray
    EVP – External Communications & Brand, Rolls-Royce plc
    Tel +44 (0) 7810 850055
    [email protected]


    Continue Reading

  • Sale of Cygnus, Greater Markham Area and Southern North Sea interests – Centrica

    1. Sale of Cygnus, Greater Markham Area and Southern North Sea interests  Centrica
    2. Centrica says total value of transaction to Spirit Energy is approximately £98 million  marketscreener.com
    3. Centrica’s Spirit sells North Sea assets to Serica Energy  Proactive Investors
    4. British Gas owner completes £98m disposal of southern North Sea gas assets  Insider Media Ltd
    5. UK’s Serica Energy to buy Southern North Sea assets for $76 million  TradingView — Track All Markets

    Continue Reading

  • Japan’s Nikkei Drops As BoJ Signals Policy Shift

    Japan’s Nikkei Drops As BoJ Signals Policy Shift

    but manufacturing is struggling and business sentiment is fading under cost pressures. Meanwhile, investors are also digesting signals from Japan’s new, dovish prime minister and the added complication of potential new US tariffs, both of which are clouding the outlook for trade and investment.

    Why should I care?

    For markets: Volatility returns as policy shifts unsettle investors.

    Japanese stocks have benefited from ultra-low rates for years, but the prospect of tighter policy is already sparking volatility. The Nikkei’s notable drop shows investors are weighing the risks of rate hikes and persistent inflation against wavering business confidence. Rate-sensitive sectors – as well as those tied to global trade – could be especially vulnerable if US tariffs escalate or Japanese rates increase faster than markets expect.

    The bigger picture: Japan’s turning point could echo throughout global finance.

    Japan has long served as a source of cheap capital for world markets. A shift toward higher rates may redirect investment flows, impact the yen, and disrupt Asian manufacturing supply chains. At the same time, changes in Tokyo’s political climate and US trade policy add layers of uncertainty, making Japan’s next moves a key watchpoint for global investors tracking the world’s third-largest economy as it tries to balance inflation and growth.

    Continue Reading

  • Malaysia: TotalEnergies Signs New Renewable Power Agreement with Google to Supply Data Centers

    Malaysia: TotalEnergies Signs New Renewable Power Agreement with Google to Supply Data Centers

    Download the Press Release

    Paris, December 16, 2025 – TotalEnergies and Google have signed a 21-year Power Purchase Agreement (PPA) to supply Google with a total volume of 1 TWh (equivalent to 20 MW) of certified renewable power from the Citra Energies solar plant in the northern Kedah province. The solar farm, which is scheduled to enter construction in early 2026, will support Google’s data center operations in Malaysia. The Malaysian Energy Commission awarded the project to TotalEnergies (49%) and its local partner MK Land (51%) in August 2023, as part of Malaysia’s Corporate Green Power Programme (CGPP).

    The agreement reflects Google’s strategy of enabling new, clean energy to the grid systems where they operate, and builds upon the PPA announced by TotalEnergies in November to supply renewable power to Google’s data centers in the United States.

    “We’re thrilled to build on our collaboration with TotalEnergies in Malaysia. This agreement is a key part of our strategy to make meaningful investments that benefit the economies where we operate. By enabling this new clean capacity, we are supporting local growth of the electricity system hosting our infrastructure”, said Giorgio Fortunato, Head of Clean Energy & Power, Asia Pacific, Google.

    “We are delighted to strengthen our collaboration with Google through this agreement to supply renewable electricity to their new data center in Malaysia”, said Sophie Chevalier, Senior Vice President Flexible Power & Integration at TotalEnergies. “This PPA illustrates our Company’s ability to offer competitive power solutions tailored to the needs of major tech groups, both in mature markets, such as the United States and Europe, and in emerging countries like Malaysia. It also contributes to achieving our target of 12% profitability in the power sector.”

    The PPA will take effect upon the project’s Financial Close, expected in the first quarter of 2026.

    ***

    TotalEnergies’ tailored PPA solutions for its clients

    The PPA with Google follows similar contracts signed by TotalEnergies with companies such as Data4, STMicroelectronics, Saint-Gobain, Air Liquide, Amazon, LyondellBasell, Merck, Microsoft, Orange and Sasol, and provides a further illustration of TotalEnergies’ ability to develop innovative solutions by leveraging its diverse asset portfolio to support its customers’ decarbonization efforts.

    TotalEnergies and electricity

    TotalEnergies is building a competitive portfolio that combines renewables (solar, onshore wind, offshore wind) and flexible assets (CCGT, storage) to deliver clean firm power to its customers. As of the end of October 2025, TotalEnergies has more than 32 GW of installed gross renewable electricity generation capacity and aims to reach 35 GW by the end of 2025, and more than 100 TWh of net electricity production by 2030.

    About TotalEnergies

    TotalEnergies is a global integrated energy company that produces and markets energies: oil and biofuels, natural gas, biogas and low-carbon hydrogen, renewables and electricity. Our more than 100,000 employees are committed to provide as many people as possible with energy that is more reliable, more affordable and more sustainable. Active in about 120 countries, TotalEnergies places sustainability at the heart of its strategy, its projects and its operations.

    TotalEnergies Contacts

    TotalEnergies on social media

    Cautionary Note
    The terms “TotalEnergies”, “TotalEnergies company” or “Company” in this document are used to designate TotalEnergies SE and the consolidated entities that are directly or indirectly controlled by TotalEnergies SE. Likewise, the words “we”, “us” and “our” may also be used to refer to these entities or to their employees. The entities in which TotalEnergies SE directly or indirectly owns a shareholding are separate legal entities. TotalEnergies SE has no liability for the acts or omissions of these entities. This document may contain forward-looking information and statements that are based on a number of economic data and assumptions made in a given economic, competitive and regulatory environment. They may prove to be inaccurate in the future and are subject to a number of risk factors. Neither TotalEnergies SE nor any of its subsidiaries assumes any obligation to update publicly any forward-looking information or statement, objectives or trends contained in this document whether as a result of new information, future events or otherwise. Information concerning risk factors, that may affect TotalEnergies’ financial results or activities is provided in the most recent Registration Document, the French-language version of which is filed by TotalEnergies SE with the French securities regulator Autorité des Marchés Financiers (AMF), and in the Form 20-F filed with the United States Securities and Exchange Commission (SEC).

    Continue Reading

  • stc Group signs a five-year agreement with Ericsson – Ericsson

    1. stc Group signs a five-year agreement with Ericsson  Ericsson
    2. stc Group Signs Five-Year Master Frame Agreement with Ericsson to Advance Digital Infrastructure  TechAfrica News
    3. Ericsson signs five-year framework agreement in Saudi Arabia  marketscreener.com
    4. stc Group signs five-year Master Frame Agreement with Ericsson to advance Saudi Arabia’s digital infrastructure  Cision News

    Continue Reading

  • PSX witnesses increase of over 1200 points in 100 index – RADIO PAKISTAN

    1. PSX witnesses increase of over 1200 points in 100 index  RADIO PAKISTAN
    2. KSE 100-share index fluctuations  Dawn
    3. Pakistan’s dual economies: stock market boom and a factory floor bust  The Express Tribune
    4. KSE-100 hits record 170,741 as SBP rate cut lifts sentiment  Profit by Pakistan Today
    5. PSX gains 877 points  Daily Times

    Continue Reading

  • Kering and Ardian finalize a joint venture agreement for a landmark New York property

    Kering and Ardian finalize a joint venture agreement for a landmark New York property

    Kering and Ardian today announced the execution of a joint venture agreement effective immediately regarding the Kering property located at 715-717 Fifth Avenue in New York City. This exceptional location on one of the world’s most iconic avenues comprises multi-level luxury retail spaces totaling approximately 115,000 sq. ft (10,700 sq. m.). 

    Following the partnership concluded earlier this year, Kering is contributing this asset to a newly created joint venture with Ardian, which will hold a 60% stake, with Kering retaining 40%. Kering’s interest in the joint venture will be accounted for under the equity method as of today.

    The transaction amounted to USD900 million (EUR766 million), with net proceeds for Kering USD690 million (EUR587 million).

    Jean-Marc Duplaix, Kering Chief Operating Officer, declared: “As we continue to execute our strategy regarding the management of our real estate portfolio, we are pursuing our successful partnership with leading investment firm Ardian. Like the investment agreement already signed in Paris, this transaction allows us to secure another long term highly prominent retail location for our Houses while enhancing our financial flexibility”. 

    Stéphanie Bensimon, Member of the Executive Committee and Head of Real Estate at Ardian, commented: “We are thrilled to continue our partnership with Kering. 715-717 Fifth Avenue offers exceptional visibility and long-term value.
    This marks Ardian’s first real estate investment in the United States and our strategic expansion into this highly attractive market.”

    Omar Fjer, Head of Real Estate France and Managing Director at Ardian, concluded: “This transaction reflects Ardian’s expertise in structuring innovative partnerships and securing assets with exceptional fundamentals. We are truly committed to acquiring and managing ultra prime assets in the most sought-after locations, which deliver lasting value for our stakeholders.”
     

     

    About Kering

    Kering is a global, family-led luxury group, home to people whose passion and expertise nurture creative Houses across ready-to-wear and couture, leather goods, jewelry, eyewear and beauty: Gucci, Saint Laurent, Bottega Veneta, Balenciaga, McQueen, Brioni, Boucheron, Pomellato, Dodo, Qeelin, Ginori 1735, as well as Kering Eyewear and Kering Beauté. Inspired by their creative heritage, Kering’s Houses design and craft exceptional products and experiences that reflect the Group’s commitment to excellence, sustainability and culture. This vision is expressed in our signature: Creativity is our Legacy. In 2024, Kering employed 47,000 people and generated revenue of €17.2 billion.

    Contacts

    Press

    Emilie Gargatte      +33 (0)1 45 64 61 20      emilie.gargatte@kering.com 
    Caroline Bruel      +33 (0)1 45 64 62 53      caroline.bruel-ext@kering.com 

    Analysts/investors

    Philippine de Schonen      +33 (0)6 13 45 68 39       philippine.deschonen@kering.com 
    Aurélie Husson-Dumoutier      +33 (0)1 45 64 60 45      aurelie.husson-dumoutier@kering.com 

     
    About Ardian

    In a world of constant evolution, Ardian stands out for its ability to anticipate, adapt, and turn challenges into opportunities. As a global, diversified private markets firm with 22 offices and more than 350 investment professionals worldwide, we provide investment and customized solutions that reflect new economic dynamics and help our clients remain resilient in a changing world. We deliver multi-local expertise and long-term performance for our investors and partners as well as shared value for the broader society. Since Ardian’s inception in 1996, our pioneering approach to diversification and our ability to offer tailor-made solutions at scale have remained the heart of our strategy. Through commitment, knowledge and technology, we bring lasting value to our companies and contribute positively to the whole industry. Ardian currently manages or advises $196bn for more than 1,890 clients worldwide across Private Equity, Real Assets, and Credit. Ardian. Mastering change for lasting value.

    ardian.com

    Contacts

    Press

    Headland      ardian@headlandconsultancy.com  
     

    Continue Reading

  • Dual Bispecifics May Redefine Management of EMD

    Dual Bispecifics May Redefine Management of EMD

    Combining teclistamab and talquetamab deepens the depth and durability of response in patients with relapsed/refractory multiple myeloma with extramedullary disease (EMD), according to an international trial. Nearly 80% of patients achieved an overall response rate with a manageable safety profile through this novel dual-targeted approach, according to study outcomes recently published in the New England Journal of Medicine.

    Advertisement

    Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

    These results exceeded standard therapies, including bispecific monotherapies and BCMA CAR T-cell therapy, for a population of patients who usually have a dire prognosis. “It’s exciting to see that combining two bispecifics together is providing durable responses in patients whose survival rates have typically been quite poor,” says Shahzad Raza, MD, study co-author and a hematologist/oncologist at Cleveland Clinic Cancer Institute. “These outcomes represent a bold step forward that has the potential to be practice changing.”

    The bispecific antibody teclistamab targets BCMA, while the bispecific antibody talquetamab targets GPRC5D. As monotherapies, teclistamab and talquetamab each provided modest benefits to patients with EMD. However, early research found combining the two medications made a notable difference.

    This study focused on patients with EMD, including those with nonsecretory or oligosecretory myeloma, who are generally excluded from clinical studies. The study outcomes were presented previously at the European Hematology Society (EHA), International Myeloma Society (IMS) and most recently at the American Society of Hematology (ASH) annual meetings.

    Background

    True EMD, which is defined as soft-tissue plasmacytomas that are not contiguous to the bone, is a highly aggressive form of multiple myeloma and is associated with dismal outcomes. Historically, survival rates for those with EMD have been around one to two years.

    Patients with EMD may initially respond to conventional treatments but the responses tend to be suboptimal and inferior to those without EMDs.

    Study design

    This phase 2 extension study was performed on talquetamab plus teclistamab exclusively in patients with drug-resistant, true extramedullary myeloma. The primary end point was overall response. Secondary end points included the duration of response, progression-free survival, overall survival and safety.

    The RedirecTT-1 trial enrolled 90 patients, who received a combination of 0.8 mg per kg of body weight of talquetamab and 3.0 mg/kg of teclistamab every two weeks, with the option to switch to once a month dosing based either on confirmed ≥VGPR (very good partial response) after cycle 4 or the physician’s discretion after cycle 6. Patients’ progress was monitored via full-body PET CT scans as well as MRIs, blood work and bone marrow biopsies.

    Study outcomes

    Of this population of patients with drug resistance and true extramedullary disease, most responded to the combination of talquetamab and teclistamab. Seventy-nine percent of the 90 patients in the study achieved an overall response rate, including 54% who achieved a complete response. The median progression-free survival was 15.4 months.

    Responses were consistent across tumor burden, cytogenetics, organ involvement and number of extramedullary sites.

    More than 76% of responders switched to monthly dosing after cycles 4-6. This change in dosing did not diminish responses. In fact, 93% deepened or maintained response after switching.

    Side effects

    The rate of adverse events was consistent with previous studies of these agents delivered as monotherapies and did not increase as a result of combining the two therapies. Few patients discontinued treatment due to adverse events, and no new safety signals were indicated. Oral toxicities were mainly grades 1-2, with only 4% having grades 3-4.

    Infection rates were high but manageable and seen during the early treatment course. The researchers found that monthly administration of IVIG helped lower infection rates. Other toxicities were manageable.

    Adverse events

    Five patients died due to infection, one from pneumonia due to COVID-19, one from pneumonia due to klebsiella infection, one from sepsis due to klebsiella infection, one from pneumonia due to unspecified infection and one from pseudomonal sepsis.

    What’s next

    “I’m grateful to our institute, my colleagues and our patients who participated in this groundbreaking research,” says Dr. Raza. “This unique combination of therapies may be a game changer for this group of patients who previously had few treatment options available to them.”

    Cleveland Clinic Cancer Institute continues to investigate new therapies such as trispecific antibodies, bispecific T-cell engagers and allogenic CAR-T for treating multiple myeloma.

    Hear our podcast with Dr. Raza about the RedirecTT-1 trial.

    Continue Reading

  • Speech by Deputy Prime Minister and Minister for Trade and Industry Gan Kim Yong at the Opening of Exxon Mobil Singapore’s Resid Upgrade Facility

    Speech by Deputy Prime Minister and Minister for Trade and Industry Gan Kim Yong at the Opening of Exxon Mobil Singapore’s Resid Upgrade Facility

    Continue Reading